Incidence of myeloproliferative hypereosinophilic syndrome in the United States and an estimate of all hypereosinophilic syndrome incidence.
作者信息
Crane Martin M, Chang Cindy Ma, Kobayashi Monica G, Weller Peter F
出版信息
J Allergy Clin Immunol. 2010 Jul;126(1):179-81. doi: 10.1016/j.jaci.2010.03.035.
Abstract
摘要
相似文献
1
Incidence of myeloproliferative hypereosinophilic syndrome in the United States and an estimate of all hypereosinophilic syndrome incidence.
J Allergy Clin Immunol. 2010 Jul;126(1):179-81. doi: 10.1016/j.jaci.2010.03.035.
2
The results of imatinib therapy for patients with primary eosinophilic disorders.
Eur J Haematol. 2006 Jun;76(6):535-6. doi: 10.1111/j.1600-0609.2006.00652.x. Epub 2006 Apr 11.
3
[Disorders with eosinophilia, treatment of hypereosinophilic syndrome].
Orv Hetil. 2005 May 1;146(18 Suppl 1):911-6.
4
Chronic eosinophilic leukemias and the myeloproliferative variant of the hypereosinophilic syndrome.
Immunol Allergy Clin North Am. 2007 Aug;27(3):377-88. doi: 10.1016/j.iac.2007.06.001.
5
A multicenter analysis of the FIP1L1-alphaPDGFR fusion gene in Japanese idiopathic hypereosinophilic syndrome: an aberrant splicing skipping the alphaPDGFR exon 12.
Ann Hematol. 2007 Dec;86(12):855-63. doi: 10.1007/s00277-007-0357-8. Epub 2007 Aug 15.
6
Imatinib Treatment of Lymphomatoid Papulosis Associated with Myeloproliferative Hypereosinophilic Syndrome Presenting the FIP1L1-PDGFRA Fusion Gene.
Acta Derm Venereol. 2017 Jul 6;97(7):855-857. doi: 10.2340/00015555-2669.
7
Idiopathic hypereosinophilic syndrome in children: report of a 7-year-old boy with FIP1L1-PDGFRA rearrangement.
J Pediatr Hematol Oncol. 2005 Dec;27(12):663-5. doi: 10.1097/01.mph.0000193467.06938.77.
8
Multilineage involvement of the fusion gene in patients with FIP1L1/PDGFRA-positive hypereosinophilic syndrome.
Br J Haematol. 2006 Feb;132(3):286-92. doi: 10.1111/j.1365-2141.2005.05863.x.
9
10
Unique association of myeloid neoplasm with eosinophilia and abnormalities of PDGFRA with TTP.
W V Med J. 2013 Mar-Apr;109(2):6-9.
引用本文的文献
1
Case Report: Idiopathic hypereosinophilic syndrome presenting with gastrointestinal involvement mimicking IBD: a diagnostic challenge.
Front Med (Lausanne). 2025 Aug 1;12:1595193. doi: 10.3389/fmed.2025.1595193. eCollection 2025.
2
Clinical and immunological biomarkers in hypereosinophilic syndrome: the second step after diagnostic algorithms.
Front Med (Lausanne). 2025 Jul 2;12:1600728. doi: 10.3389/fmed.2025.1600728. eCollection 2025.
3
Burden of hypereosinophilic syndromes in the United States: Patients' perspective.
J Allergy Clin Immunol Glob. 2025 May 28;4(3):100501. doi: 10.1016/j.jacig.2025.100501. eCollection 2025 Aug.
4
Reversible Dementia With Hypereosinophilia: An Intricate Connection.
Cureus. 2025 Jun 14;17(6):e86009. doi: 10.7759/cureus.86009. eCollection 2025 Jun.
5
Steroid-sparing benefits of biologic use in hypereosinophilic syndrome and substantial disease burden across subtypes.
Front Allergy. 2025 May 23;6:1605397. doi: 10.3389/falgy.2025.1605397. eCollection 2025.
6
Loeffler endocarditis revealing chronic eosinophilic leukaemia with FIP1L1-PDGFRA rearrangement: a case report.
Eur Heart J Case Rep. 2025 May 2;9(5):ytaf218. doi: 10.1093/ehjcr/ytaf218. eCollection 2025 May.
7
Improving patient outcomes: Mepolizumab's impact in IL-5-mediated diseases.
Lung India. 2025 May 1;42(3):231-244. doi: 10.4103/lungindia.lungindia_442_24. Epub 2025 Apr 29.
8
Biologic Agents in Idiopathic Hypereosinophilic Syndrome.
Pharmaceuticals (Basel). 2025 Apr 8;18(4):543. doi: 10.3390/ph18040543.
9
Chronic Eosinophilic Leukemia Positive for FIP1L1-PDGFRa.
Cureus. 2025 Feb 24;17(2):e79548. doi: 10.7759/cureus.79548. eCollection 2025 Feb.
10
Therapeutic Challenges and Emerging Strategies for and Mutations in a -Positive Myeloproliferative Neoplasm: A Case Report.
Life (Basel). 2025 Mar 20;15(3):505. doi: 10.3390/life15030505.
本文引用的文献
1
Five years since the discovery of FIP1L1-PDGFRA: what we have learned about the fusion and other molecularly defined eosinophilias.
Leukemia. 2008 Nov;22(11):1999-2010. doi: 10.1038/leu.2008.287. Epub 2008 Oct 9.
2
Epidemiology of myelodysplastic syndromes and chronic myeloproliferative disorders in the United States, 2001-2004, using data from the NAACCR and SEER programs.
Blood. 2008 Jul 1;112(1):45-52. doi: 10.1182/blood-2008-01-134858. Epub 2008 Apr 28.
3
Approach to the therapy of hypereosinophilic syndromes.
Immunol Allergy Clin North Am. 2007 Aug;27(3):551-60. doi: 10.1016/j.iac.2007.07.006.
4
Clinical overview of hypereosinophilic syndromes.
Immunol Allergy Clin North Am. 2007 Aug;27(3):333-55. doi: 10.1016/j.iac.2007.07.007.
5
Approaches to the treatment of hypereosinophilic syndromes: a workshop summary report.
J Allergy Clin Immunol. 2006 Jun;117(6):1292-302. doi: 10.1016/j.jaci.2006.02.042. Epub 2006 May 3.
6
Hypereosinophilic syndrome: an update.
Am J Hematol. 2005 Oct;80(2):148-57. doi: 10.1002/ajh.20423.
7
A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome.
N Engl J Med. 2003 Mar 27;348(13):1201-14. doi: 10.1056/NEJMoa025217.
Zotero 插件